Charles Schwab Investment Management Inc. increased its position in shares of LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) by 36.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,104,453 shares of the company's stock after purchasing an additional 297,723 shares during the period. Charles Schwab Investment Management Inc. owned 0.29% of LifeStance Health Group worth $7,731,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. raised its stake in shares of LifeStance Health Group by 6.1% in the 3rd quarter. Principal Financial Group Inc. now owns 4,116,766 shares of the company's stock worth $28,817,000 after buying an additional 235,316 shares in the last quarter. Jennison Associates LLC raised its position in LifeStance Health Group by 9.5% in the third quarter. Jennison Associates LLC now owns 2,136,942 shares of the company's stock worth $14,959,000 after acquiring an additional 184,896 shares in the last quarter. Dimensional Fund Advisors LP raised its position in LifeStance Health Group by 82.0% in the second quarter. Dimensional Fund Advisors LP now owns 1,016,452 shares of the company's stock worth $4,991,000 after acquiring an additional 457,930 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in LifeStance Health Group in the second quarter worth about $4,326,000. Finally, Bank of New York Mellon Corp raised its holdings in shares of LifeStance Health Group by 3.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 451,102 shares of the company's stock worth $2,215,000 after purchasing an additional 15,309 shares in the last quarter. Institutional investors own 85.50% of the company's stock.
LifeStance Health Group Trading Up 0.1 %
Shares of LFST stock traded up $0.01 during trading hours on Wednesday, reaching $7.19. 1,095,883 shares of the stock traded hands, compared to its average volume of 1,527,177. LifeStance Health Group, Inc. has a 1-year low of $4.64 and a 1-year high of $9.20. The business has a fifty day moving average price of $7.15 and a 200 day moving average price of $6.30. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $2.75 billion, a PE ratio of -27.62 and a beta of 1.28.
LifeStance Health Group (NASDAQ:LFST - Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.05. The company had revenue of $312.70 million for the quarter, compared to the consensus estimate of $302.25 million. LifeStance Health Group had a negative net margin of 7.90% and a negative return on equity of 6.66%. The company's revenue was up 18.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.17) EPS. On average, equities research analysts forecast that LifeStance Health Group, Inc. will post -0.2 EPS for the current year.
Insider Activity
In other news, Director Robert Bessler sold 75,000 shares of the company's stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $7.54, for a total value of $565,500.00. Following the transaction, the director now directly owns 1,424,447 shares of the company's stock, valued at approximately $10,740,330.38. This represents a 5.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 6.60% of the stock is owned by corporate insiders.
Analyst Ratings Changes
A number of analysts recently commented on LFST shares. UBS Group dropped their target price on shares of LifeStance Health Group from $9.00 to $7.50 and set a "neutral" rating on the stock in a report on Thursday, August 15th. Barclays upped their price target on LifeStance Health Group from $6.00 to $7.00 and gave the company an "underweight" rating in a report on Monday, November 11th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $8.50.
View Our Latest Analysis on LFST
About LifeStance Health Group
(
Free Report)
LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.
Featured Stories
![Institutional Ownership by Quarter for LifeStance Health Group (NASDAQ:LFST)](https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&Symbol=LFST)
Before you consider LifeStance Health Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeStance Health Group wasn't on the list.
While LifeStance Health Group currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.